SVB Wealth LLC Takes $325,000 Position in Edwards Lifesciences Co. (NYSE:EW)

SVB Wealth LLC acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,386 shares of the medical research company’s stock, valued at approximately $325,000.

Several other large investors have also bought and sold shares of EW. Abacus Planning Group Inc. increased its holdings in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after buying an additional 140 shares in the last quarter. Bowman & Co S.C. grew its holdings in shares of Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after acquiring an additional 148 shares during the last quarter. Pegasus Asset Management Inc. raised its position in shares of Edwards Lifesciences by 0.4% during the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock worth $3,156,000 after purchasing an additional 159 shares during the period. Mount Yale Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 1.9% during the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after purchasing an additional 162 shares during the last quarter. Finally, Seascape Capital Management boosted its position in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after purchasing an additional 174 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $70.78, for a total transaction of $796,275.00. Following the transaction, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,150,791.86. This trade represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,739 shares of company stock worth $2,799,104 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $72.89 on Thursday. The stock has a 50-day moving average of $72.45 and a 200-day moving average of $70.35. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $42.99 billion, a PE ratio of 10.46, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on EW shares. Citigroup upped their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.